Autologous Renal Cell Vaccine Based On Dnp Modified Cells

Name: Autologous Renal Cell Vaccine Based On Dnp Modified Cells in Renal Cell Cancer
Creator: Floatz
License: https://terminal.floatz.ai/terms

Renal Cell Cancer

Hadassah Medical OrganizationvaccinePhase 1/2Dormant

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 89/ 100

Competitive context

298 Active assets in the Renal Cell Cancer cohort.

Asset / Sponsor	Phase	Rating
gw786034 Imbioray (Hangzhou) Biomedicine Co., Ltd.	Phase 4	BBB
Sorafenib Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Phase 4	BBB
Belzutifan Vall d'Hebron Institute of Oncology	Phase 3	BBB
Alpha-Interferon National Cancer Institute (NCI)	Phase 3	BBB
CYCLOSPORIN A National Cancer Institute (NCI)	Phase 2	BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →